Table 2 Number of cases and ROR (95% CI) of each NSAID-induced lower gastrointestinal tract injury adverse event reported in JADER.

From: Preventive effect of rebamipide on NSAID-induced lower gastrointestinal tract injury using FAERS and JADER

 

LGTI

Other AE

LGTI (%)

ROR

95% CI

[I]

Loxoprofen (+)

236

23,026

1.02

1.61

1.40–1.84

Loxoprofen (−)

2271

357,251

0.63

[III]

Diclofenac (+)

274

9395

2.91

4.84

4.26–5.50

Diclofenac (−)

2233

370,882

0.60

[II]

Loxoprofen

 Rebamipide (+)

36

6066

0.59

0.50

0.35–0.71

 Rebamipide (−)

200

16,960

1.17

[IV]

Diclofenac

 Rebamipide (+)

21

1518

1.38

0.43

0.27–0.67

 Rebamipide (−)

253

7877

3.21

  1. Lower gastrointestinal tract injury of single-drug NSAIDs [I], [III]. Lower gastrointestinal tract injury with concomitant use of rebamipide and NSAIDs [II], [IV].
  2. LGTI lower gastrointestinal tract injury, AE adverse event.
Back to article page